D‐Tryptophan‐6‐luteinizing hormone‐releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia

Luis Schwarzstein, Néstor J. Aparicio, Andrew V. Schally

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


D-Tryptophan-6-LH-RH was assessed in the treatment of patients with normogonadotropic oligoasthenozoospermia in 18 subjects selected on the basis of at least 3 spermiograms, long standing infertility, normal LH, FSH, prolactin and testosterone serum levels and lack of evidence of any other pathologic involvement. Testicular biopsies performed on these patients showed hypospermatogenesis with foci of alteration at the spermatid stage in some of them. D-Trp-6-LH-RH was administered im for 90 days as a dose of 5 μg every 2 days, 10 μg daily or 10 μg daily every 2 days. These was no significant improvement in the concentration of spermatozoa or in the motility and vitality parameters. Moreover, in 5 patients who received 10 μg daily, basal levels of LH and FSH and the response to LH-RH, decreased significantly during treatment, D-Trp-6-LH-RH at the dose used in this study does not seem useful for the treatment of oligoasthenozoospermia normogonadotropic patients.

Original languageEnglish (US)
Pages (from-to)171-178
Number of pages8
JournalInternational Journal of Andrology
Issue number2
StatePublished - Apr 1982
Externally publishedYes


  • LH‐RH agonists
  • oligoasthenozoospermia treatment

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Reproductive Medicine
  • Urology


Dive into the research topics of 'D‐Tryptophan‐6‐luteinizing hormone‐releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia'. Together they form a unique fingerprint.

Cite this